MC# 23-08 - DEKA-1 a dose-finding Phase I trial: evaluating safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy

  • Agent(s): DK210 (EGFR)
  • Disease Type(s): Colorectal, Melanoma, Solid Tumor, Renal, Squamous Cell, Lung-NSCLC
  • Phase(s): I
  • Drug Classification(s): Targeted Therapy, Cytokines, Immunotherapy
  • Molecular Target(s): EGFR

Mechanism of Action

EGFR-targeting IL2/IL10


In this study, the sponsor and investigators want to learn:

  • How much of DK210 (EGFR) can be given with an acceptable level of side effects alone or in combination with immunotherapy, chemotherapy, or radiation
  • The effects of DK210 (EGFR) (good and bad) alone or in combination with immunotherapy, chemotherapy, or radiation
  • How much of DK210 (EGFR) is absorbed into the blood and how fast it is removed
Inclusion Criteria
  • ECOG performance status of 0-1
  • Life expectancy of >3 months according to the investigator's judgment
  • By local standard confirmed progressive metastatic and/or locally advanced unresectable solid cancer with EGFR overexpression or amplification
  • Measurable disease, defined as at least one (non-irradiated) lesion measurable on CT/MRI or bone scan as defined by RECIST 1.1
  • Progressive disease (PD) at study entry defined as one or more of the following criteria:
    • Clinical PD with performance decline, clinical symptoms and/or observed tumor growth
    • PD documented with imaging showing at least 20% growth (largest diameter) and/or new lesions
  • Adequate cardiovascular, hematological, liver, and renal function
  • Subjects have failed one or more lines of systemic therapy and have not been operated on or receiving anti-cancer medication for at least 4 weeks
  • Males and females of childbearing potential must agree to use effective contraception starting prior to the first day of treatment and continuing during treatment
  • Additional criteria may apply
Exclusion Criteria
  • Subjects with documented diffuse peritoneal disease or persistent abundant ascites
  • Subjects with known prolonged QTc interval
  • Concomitant or recent (<4 weeks or 5 half-lives of the last treatment, whichever is shorter) treatment with agents with anti-tumor activity, including immunotherapies, or experimental therapies.  Bone treatments and supportive care can be continued.
  • Major surgery within 4 weeks, radiation therapy for the treatment of metastases within less than 3 weeks (if single fraction of radiotherapy, then within 2 weeks), and radionuclide therapy for the treatment of metastases within 4 weeks prior to screening
  • Uncontrolled intercurrent illness including, but not limited to, ongoing and uncontrolled infection (TBC, COVID or HIV patients treated with at least two anti-retroviral drugs and control of their infection with at least 500/mm3 CD4+ T-cells in their blood and patients cured from Hepatitis B or C (i.e negativity of PCR) and liver function compatible with eligibility criteria are allowed to participate), multiple myeloma, multiple sclerosis, myasthenia gravis, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirement
  • Any other conditions that, in the investigator's opinion, might indicate the subject to be unsuitable for the study
  • Additional criteria may apply


  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info:

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 23-08